After Drug Is Granted Orphan Status, Hospitals Can Be Left Paying Millions For Treatment That Was Cheap, Attainable

Drugmakers argue that they've pumped millions into research and so they can charge a lot more for drugs that used to be available cheaply. But experts find flaws in their logic. In other pharmaceutical news: the price of insulin and CVS' fourth-quarter profits.

from Kaiser Health News https://ift.tt/3bBFvDZ